A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. - Wikidata - wikimedia - TriplyDB

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.

http://www.wikidata.org/entity/Q30413350

about

Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation Management of hepatitis c genotype 4 in the liver transplant setting Management of immunosuppressant agents following liver transplantation: Less is more Liver transplantation for viral hepatitis in 2015 Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management Impact of new treatment options for hepatitis C virus infection in liver transplantation Hepatitis C cirrhosis: New perspectives for diagnosis and treatment Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in Hepatitis C: New challenges in liver transplantation Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis Management of hepatitis C infection before and after liver transplantation HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Recurrent hepatitis C after liver transplant Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis Predictive factors associated with hepatitis C antiviral therapy response.Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.Living-donor liver transplantation and hepatitis C Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.Current Issues in Liver Transplantation.Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX).Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment.Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience.Hepatitis C recurrence: the Achilles heel of liver transplantation.Future treatments of cirrhosis.Recurrent HCV after liver transplantation-mechanisms, assessment and therapy.Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation.Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients.PRO view: treat to prevent recurrence of HCV.Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy.Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation.Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection.

P2860

Q24202008-0AC3919F-5D7A-42A1-81D9-C3DDE68851FA Q26749326-98A3F075-A88E-49A3-8CF4-10DDD10788BA Q26770033-A563F1A9-629C-477C-90B6-AAEFDC140B7E Q26773224-E1F43BD8-16C2-402D-A0CE-C1687CB0D1CA Q26781984-6B8C5A80-24EC-460A-AE69-0787AC00DE78 Q26782017-1DA03E31-72AC-4D01-B86C-44F2D4144423 Q26799924-7C1C24F2-E86D-486F-9591-0D4C52EBF48E Q26820811-9768CA93-A440-479F-8401-806C02853BCE Q26999368-B6608ADF-00E5-41EF-A956-2C36FAFA31B7 Q28070260-2DE6C460-69BD-4D3A-AD18-B49CA576463F Q28081250-9F67AF24-16E4-47D9-B688-8665EBBCF2E5 Q31012317-497188A9-2095-45F8-B6B3-809AE399D556 Q33426112-768D7403-CD0A-453E-ACDF-DC007D2DDE69 Q34067825-5BA99E8F-FBAB-493F-9061-D856EC5B8ABB Q34675037-FA3B4A5A-B43E-469C-984C-9A0386C54732 Q34926607-494E4002-78DF-4537-A2FE-7A5DD71C5CAE Q35270937-A96DED72-5E45-427A-9E5C-89E0D6E2D06A Q35790397-AD19B4EA-94D5-4574-9CF8-8947EE5956B4 Q36197501-80245C45-CA7F-4743-99D7-E053DE82623B Q36587253-54F76E80-3771-449D-BC29-E0B7AE491531 Q36624431-22738F28-B728-4877-B91E-B50C6D02F71E Q36875036-C0F29821-BAD3-49B9-AEDF-205C7B513B7F Q36916657-D2D5CB4F-A811-4B5B-AD19-9845360AC57C Q37314134-40FA632F-DEC0-414A-96BB-11A1CE5B3744 Q37625268-E282B189-F106-4239-B20C-13CF4EE525AB Q37628461-73D9ADA8-F58F-489D-B587-AFFE4D303636 Q38174194-D48046AC-D69B-4F73-90B1-6216F559C812 Q38218607-09F8E2AD-A6CF-46ED-95AE-D4C7E46951CE Q38229320-BC6E9F36-C0E9-4FB6-A1BA-D6E27C7601F4 Q38689820-E5F76A1F-1D47-41BA-9C5A-A7CC51A4210B Q38723427-3645DAD8-E9ED-4642-A982-02321060F848 Q39505304-D7D8ACAE-4B9D-41DE-AA7E-4C0C19B97258 Q40444467-9F5BD9CD-D378-4789-8175-95215027A1FC Q40579236-EDD4E203-A280-4AFA-8FBE-BD5A7B430D92 Q41285334-0A805A75-A3FB-420E-9092-6DB7F8E2175C Q42158349-DA8E4F9D-32C4-4B30-A6F6-125BE9781895 Q42203060-8FD9CDD1-AC4C-4BE8-84A1-95C33A9C96FA Q42213969-C5EFAE73-1920-4967-A9CE-842466E2AC26 Q42260788-90E05A1A-DC4E-48F3-B56F-F79F46B53828 Q42287044-0E39543E-9966-4A78-9658-333B2DDD9F01

P2860

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.

http://www.wikidata.org/entity/Q30413350

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A randomized controlled trial ...... C after liver transplantation.

@ast

A randomized controlled trial ...... C after liver transplantation.

@en

type

label

A randomized controlled trial ...... C after liver transplantation.

@ast

A randomized controlled trial ...... C after liver transplantation.

@en

prefLabel

A randomized controlled trial ...... C after liver transplantation.

@ast

A randomized controlled trial ...... C after liver transplantation.

@en

P1433

Q30413350-72E1764E-0B00-4A85-8E94-79E18FFFF670

P1476

Q30413350-CE19994F-9796-4BFD-B0DE-426B3D2B9999

P2093

Q30413350-0803DC6C-1E0F-4527-94C0-6534A6F308F5

Q30413350-103879A2-4FA2-4A61-BFAE-073C0588305B

Q30413350-12581C27-79C5-4EEA-8992-A088C38C3CE7

Q30413350-2D1D01D8-B064-477E-9D59-664A24826B32

Q30413350-3DB08148-9AEB-4A02-A707-E3F188B369C6

Q30413350-4B8765B2-47E3-42D6-9B69-E29645C7B8FD

Q30413350-5A410CDF-3CDC-4003-926D-4E922E2525D6

Q30413350-8D3FA8F2-165A-49A2-AEEA-1D5DBA135C55

Q30413350-9DFCB35D-B05B-4BAB-B6A8-8BB73F20D904

Q30413350-9F090781-6E7D-45EB-BD5C-10EC89392972

P2860

Q30413350-210D8A82-8D15-4F18-9FA5-B2822478A5FD

Q30413350-222819FF-CFC9-4B02-BD4D-E9A87B3511E8

Q30413350-267910EB-2073-4CB5-98AB-9CCB6F4C8E00

Q30413350-2A4A803E-23ED-419B-8422-3EB293CEAF2D

Q30413350-3B271352-5AD1-4D92-B4E6-6EED0D2D3437

Q30413350-3ECD76CC-B0DB-4C38-9350-F044DF2F3DEF

Q30413350-5B70148C-C344-4661-9FB6-B193B72EA4D8

Q30413350-69B25145-6C65-478D-BB76-602D0AA8B3F0

Q30413350-6C7E0EEC-DA69-4BA9-B165-FCE506F573F9

Q30413350-6DA53384-A4F5-4A39-8F95-F6B3F73B685A

P304

Q30413350-EAEC49AA-B6A6-4827-B66F-9F2811900D04

P31

Q30413350-199670D0-9FDA-47BF-876B-6B9A0C6E894C

P356

Q30413350-F634300E-6D21-4D0A-8E8D-A98A0BC70FBA

P407

Q30413350-779A80E9-D41B-4917-9006-447BB595C983

P433

Q30413350-4E7584AB-7956-4CED-8344-2A8E8EA7DFE1

P478

Q30413350-DF57CEAE-96D9-4C24-B3EC-CFC051258B52

P577

Q30413350-7894EF5B-3D1E-4A71-B3B2-84C477A5B581

P698

Q30413350-7050EDA9-C88B-40B0-B7C4-6C2F71CE9E59

P921

Q30413350-3621FD81-B50F-4D75-B95F-53C1843E7042

P932

Q30413350-38DAD0EB-BBA8-4E28-8DCD-B9B59E57850A

P356

P1433

P1476

A randomized controlled trial ...... C after liver transplantation.

@en

P2093

Abdullah M S Al-Osaimi

http://www.w3.org/2001/XMLSchema#string

Adult-to-Adult Living Donor Liver Transplantation Cohort Study

http://www.w3.org/2001/XMLSchema#string

Anna S Lok

http://www.w3.org/2001/XMLSchema#string

Brenda W Gillespie

http://www.w3.org/2001/XMLSchema#string

Del R Rodrigo

http://www.w3.org/2001/XMLSchema#string

Gregory T Everson

http://www.w3.org/2001/XMLSchema#string

James E Everhart

http://www.w3.org/2001/XMLSchema#string

Laura M Kulik

http://www.w3.org/2001/XMLSchema#string

Mitchell L Shiffman

http://www.w3.org/2001/XMLSchema#string

Norah A Terrault

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Diagnosis, management, and treatment of hepatitis C: an update

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.

Estimating population distributions when some data are below a limit of detection by using a reverse Kaplan-Meier estimator.

Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.

Natural history and management of hepatitis C infection after liver transplantation.

What determines the natural history of recurrent hepatitis C after liver transplantation?

The association between hepatitis C infection and survival after orthotopic liver transplantation.

P304

1752-1762

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.25976

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22821361

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation

P932

3510348

http://www.w3.org/2001/XMLSchema#string